TF opens giant Singapore storage and supply hub

By Fiona BARRY contact

- Last updated on GMT

Singapore skyline: Thermo Fisher's new site measures 70,000 sq ft
Singapore skyline: Thermo Fisher's new site measures 70,000 sq ft

Related tags: Thermo fisher, Revenue, Supply and demand, Singapore

Thermo Fisher has opened a 70,000 sq ft GMP clinical supply hub in Singapore.

The company said the site will be a “one-stop service for clinical supplies,​” offering GMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution including cold chain, and returns management. The facility is aimed at regional and global pharma customers.

The company opened its first clinical services facility in Singapore in 2001 and will move the country’s operations to the new site on Toh Guan Road, Jurong East, part of a Singapore biotech hub. The 70,000 sq ft facility (6,500sqm) adds 60% more floor space and doubles previous cold chain capacity.

The facility has expanded Thermo Fisher’s storage system for its clinical supplies with a climate control energy use system that reduces the facility's carbon footprint, and a general building monitoring system that updates employees on the facility's conditions.

Asia-Pacific
"Asia Pacific continues to be our fastest-growing market and a central contributor to our growth,​" said Leon Wyszkowski, a Thermo Fisher VP.

"For nearly 15 years, Singapore has been the central hub for our Asia-Pacific operations due to its strategic location. With the opening of our larger and well-equipped facility, we aim to continue to build on our Singapore facility further and on the expertise of our local team, to strengthen our regional and global presence in the clinical supplies industry.​"

Thermo Fisher Scientific last month reported Q3 earnings of $4.12bn, and earnings per share of $1.80. Earlier this year the division launched Ion S5 and Ion S5 XL next-generation sequencing platforms, new immunodiagnostic tests and instruments, and a high-throughput HPLC. It attributed revenue growth to demand from Chinese biopharma, among other factors.

Related news

Related products

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars